(“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that the Company will present data from tissue microarrays showing high expression of. By continuing to use our service, you agree to our use of cookies. 25 to $1. 10% least volatile stocks in CA Market. TO) on CEO. is a speaker and consultant of Theratechnologies. Theratechnologies (THTX) Stock Price, News & Analysis $1. The financial results presented in this press release are taken from the. 4% annually. Cookies are used to offer you a better browsing experience and to analyze our traffic. 30, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. MONTREAL, April 12, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. 33 +0. Stockhouse. (TH. Further. com. The SORT1 receptor plays a significant role in protein internalization, sorting and trafficking. MONTREAL, Feb. 9% more than in 2021. Theratechnologies reduces R&D head count to compensate for sales setback. (2022-10-03 | TSX:TH) Theratechnologies' Trogarzo® Approved by FDA for 30-Second Intravenous (IV) Push, Simplifying HIV Treatment for Heavily Treatment-Experienced Population. 68 to a day high of $1. We also use them to share usage. Biopharma Theratechnologies (NASDAQ:THTX) Friday announced that a study evaluating an intramuscular (IM) method of administration for its therapy, Trogarzo, did not meet the primary endpoint. Browse posts by Sector and Subsector. MONTREAL, March 29, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Get the latest Theratechnologies Inc (THTX) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. The Notes were issued under a trust indenture dated as of June 19, 2018, by and among Theratechnologies and Computershare Trust Company of Canada. TH | March 7, 2023. View real-time stock prices and stock quotes for a full financial overview. Montréal, Québec, Canada . This news release constitutes a “designated news release” for the purposes of the Company’s. (THTX) stock quote, history, news and other vital information to help you with your stock trading and investing. Cookies are used to offer you a better browsing experience and to analyze our traffic. Montreal-based biopharmaceutical company Theratechnologies Inc. Theratechnologies Inc. The Montreal-based biopharmaceutical company's consolidated net revenues for fourth quarter 2020 are expected to be between US$18. We also use them to share. -986. com. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that President and CEO, Paul Lévesque has issued an open letter to shareholders. 28, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. 89 $2. By continuing to use our service, you agree to our use of cookies. TH 48% v4,15M c1. This module allows you to check different measures of market premium (i. 2015 Peel St 11TH Fl, Montreal, Quebec, H3A 1T8, Canada. By continuing to use our service, you agree to our use of cookies. The company offers EGRIFTA and EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus. The website address for Stockhouse has changed We changed the address of the Stockhouse website from to stockhouse. We also use them to share usage. - 2023 Q3 positive adjusted EBITDA to be achieved. Theratechnologies Announces 1-for-4 Reverse Stock Split. Cookies are used to offer you a better browsing experience and to analyze our. (2022-04-27 | TSX:TH) Theratechnologies to Focus Its Commercialization Activities on the North American Territory. MONTREAL, Sept. About Theratechnologies Theratechnologies (TSX:TH) is a specialty pharmaceutical company addressing unmet medical needs to promote healthy ageing and an improved quality of life among HIV patients. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. 25, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. It’s lead investigational peptide drug conjugate linked to docetaxel, a well-established and well-characterized cytotoxic agent used in the. Theratechnologies presented the pre-clinical and clinical data gathered thus far to the SAC, which made recommendations to modify the frequency of administration, selection of tumor types and. 12, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies”, the “Company”, or “we”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has completed the previously announced consolidation of the issued. com uses cookies on this site. (2022-02-10 | TSX:TH) Theratechnologies to Announce Financial Results for Its Fourth Quarter and Full Fiscal Year 2021. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a commercial-stage biopharmaceutical company addressing unmet medical needs by bringing to market specialized therapies for people with orphan medical. We also use them to share usage information with our partners. Investor inquiries: Elif McDonald. The price has fallen in 5 of the last 10 days. Further. Theratechnologies Inc. Lead drug EGRIFTA (tesamorelin for injection) is being marketed for the reduction of excess abdominal fat in HIV-infected patients with. CALGARY, AB, May 12, 2022 /PRNewswire/ - Exro Technologies Inc. MONTREAL, Feb. Theratechnologies . Who is Theratechnologies. By continuing to use our service, you agree to our use of cookies. TH | September 5, 2023. (“Theratechnologies” or “the Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the strengthening of its global commercial. About Theratechnologies Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. 69 to $1. NEW YORK, Dec. communications@theratech. 31, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (TH. T. US Headquarters. Stockhouse. Further. com uses cookies on this site. 250 Howe Street, Suite 1400 Vancouver, British Columbia, V6C 3S7 Click to expand. MONTREAL, Jan. - Issued and outstanding common shares to be consolidated on the basis of 1 post-consolidation share for each 4 pre-consolidation shares issued and outstanding, to regain compliance with NASDAQ listing requirements. Shares of Theratechnologies are up 4. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. 71%. Philippe Dubuc Senior Vice President and Chief Financial Officer Phone: +1-438-315-6608 [email protected] uses cookies on this site. MONTREAL, July 23, 2021 /CNW Telbec/ - Theratechnologies Inc. Theratechnologies Inc. Theratechnologies Inc. com uses cookies on this site. stockhouse. 89 52. (2022-07-27 | TSX:TH) Theratechnologies Announces Closing of Funding of $40 Million Under the Terms of its Credit Agreement Stockhouse. Denis Boucher. See the latest Theratechnologies Inc stock price (THTX:XNAS), related news, valuation, dividends and more to help you make your investing decisions. 1. Cookies are used to offer you a better browsing experience and to analyze our traffic. In the United States, Trogarzo ® (ibalizumab. The company’s marketed products include Egrifta SV is indicated to reduce excess abdominal fat in human immunodeficiency virus (HIV. Company Description: Theratechnologies is pepped up on peptides. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has decided to pause the enrollment of patients in its Phase 1 clinical. , a biopharmaceutical company focused on the development and commercialization of innovative therapies, announced further changes to its operations that will see a tapering. $30. Theratechnologies Stock Price, News and Company Updates. By continuing to use our service, you agree to our use of cookies. About Theratechnologies Theratechnologies (Nasdaq: THTX) (TSX: TH) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical. The company reported ($0. Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today reported business. Theratechnologies (TH) has submitted a supplemental biologics license application (sBLA) to the U. - Cash, bonds and money market funds of US$22. Stockhouse. (“Theratechnologies” or the “Company”) (TSX: TH) today announced that it has applied to list its common shares on NASDAQ. FY2023 Revenue Guidance Range Confirmed Between $90 million and $95 million; Growth of the Commercial Portfolio in the Range of 13% and 19%. Theratechnologies (TH) provided business highlights and financial results for the second quarter and first half of fiscal year 2022; For the three- and six-month periods ending May 31, 2022, consolidated revenue was US$19,268,000 and US$37,825,000, compared to US$17,787,000 and US$33,217,000 for the same periods last year,. Cookies are used to offer you a better browsing experience and to analyze our traffic. TO) stock quote, history, news and other vital information to help you with your stock trading and investing. Last Reviewed: February 24, 2023. MONTREAL, Feb. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that the Company will present data from tissue microarrays showing high. Their THTX share price targets range from $36. It is the Company’s proprietary peptide linked to. Vancouver, Canada –– TheNewswire - April 7, 2022 - Teuton Resources Corp. The reported ($0. Stockhouse. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Stockhouse. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced preliminary efficacy data from a Phase 1 study of its lead investigational peptide-drug. Register for your free account today at data. Theratechnologies’ R&D staff is bearing the brunt of. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. 9 million and US. It’s lead investigational peptide drug conjugate linked to docetaxel, a well-established and well-characterized cytotoxic agent used in the treatment of. Theratechnologies's earnings have been declining at an average annual rate of -35. Stockhouse. Track Theratechnologies Inc. By continuing to use our service, you agree to our use of cookies. Theratechnologies Inc. TH Stock Message Board for Investors. com uses cookies on this site. (2021-01-19 | TSX:TH) Theratechnologies Announces Closing of US$46 Million Bought-Deal Public Offering, Including Full Exercise of the Over-Allotment Option. US Headquarters. October 13, 2022 07:30 ET | Source: Theratechnologies. Cookies are used to offer you a better browsing experience and to analyze our traffic. T. Betteryear2. 54% and a negative trailing twelve-month return on equity of 1,116. TH1902 combines Theratechnologies’ proprietary peptide to. Theratechnologies (TSX:TH)has indicated that Trogarzo did not meet its primary endpoints in its IM method study. By continuing to use our service, you agree to our use of cookies. MONTREAL, Oct. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and. Stockhouse. D. Theratechnologies Inc. , a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. Find the latest Theratechnologies Inc. Our research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic. Investor inquiries: Elif McDonald. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced it will report financial results and provide a business update for its second. MONTREAL, April 14, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. 22, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. H4S 2B4 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F x Form 40-F ¨Theratechnologies has established its SORT1+ Technology™ platform as an engine for the development of proprietary peptide-drug conjugates (PDCs) that target the sortilin (SORT1) receptor, which is expressed in multiple tumor types. Senior Director, Investor Relations. One reason for that is that this tier does not include penny stocks. 28 $1. (THTX) stock. MONTREAL, July 12, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Focused on small-cap companies and sectors. Theratechnologies Inc. Join the discussion: Find out what everybody’s saying about this stock on the Theratechnologies Bullboard, and check out the rest of Stockhouse’s stock forums and message boards. 15, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. We also use them to share. Cookies are used to offer you a better browsing experience and to analyze our traffic. . 04, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. T. stock price gained 1. However, only about 4% of the stocks on the OTC market fall into this category. Amendment Withdraws the Condition to File HFS Report to the FDA to Access the US$20 Million Second Tranche. US Headquarters. Their average twelve-month price target is $36. (THTX) Stock Price, Quote, latest community messages, chart, news and other stock related information. (Translation of registrant’s name into English) 2310 Alfred-Nobel Boulevard . By continuing to use our service, you agree to our use of cookies. Theratechnologies inc. THERATECHNOLOGIES INC. com uses cookies on this site. Watch list NEW Set a price target alert After Hours Last. 81 million for the quarter. T. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. In collaboration with the University of Manitoba (UM), the company demonstrated that its photodynamic compound. Fri, 17 Apr 2015 15:08:33 GMT ~ Supreme Court of Canada rules in favour of Theratechnologies. MONTREAL, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Phone Number 15143319691. com. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. TH | September 26, 2023. Canadian Commercial-Stage Biopharmaceutical Company Theratechnologies Announces NASDAQ Listing. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. - 2023 Q3 positive adjusted EBITDA to be. Proceeds to Be Used to Redeem All of the Outstanding 5. Microsoft (NDAQ:MSFT) will expand its presence in Quebec with new computing capacity and AI and. On average, they expect the company's stock price to reach $36. TH1902 Study Published in Pharmaceutics Demonstrates Inhibition of Human Sortilin (Sort1)-Positive Ovarian and Triple-Negative Breast Cancer Stem-Like Cells and Tumor Growth Sep 13. We currently market. com uses cookies on this site. Stockhouse. - Q3 2022 North American Revenue Growth of 19%. 60%. Stockhouse. View real-time stock prices and stock quotes for a full financial overview. View real-time stock prices and stock quotes for a full financial overview. Stockhouse. MONTREAL, July 31, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. By continuing to use our service, you agree to our use of cookies. Marsolais will present at the H. We changed the address of the Stockhouse website from to stockhouse. T. MONTREAL, Sept. - Q3 2022 Consolidated. Stockhouse. We currently market prescription products for people with HIV in the United States. MONTREAL, Feb. This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated December 16, 2021 to its short form base shelf prospectus dated December 14, 2021. UN) today announces steps to strengthen its financial position, including financing and disposition initiatives, and a reduction to its monthly distribution. By exploiting the SORT1 function in ligand internalization, a new anticancer treatment strategy was designed to target SORT1‐positive TNBC‐derived cells both in vitro and in two in vivo tumor xenografts. The company reported ($0. Trogarzo is a CD4-directed post-attachment HIV-1 inhibitor. Stockhouse. Stockhouse. com uses cookies on this site. 's motion for leave to commence. Message Board Total Posts: 4. Theratechnologies (TSX: TH) is a specialty pharmaceutical company addressing unmet medical needs by bringing to market specialized therapies for people with orphan medical conditions, including. Investor Relations. com. 04, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (2020-10-16 | TSX:TH) Theratechnologies Appoints Two New Board Members. By continuing to use our service, you agree to our use of cookies. This news release constitutes a. Stockhouse. Cookies are used to offer you a better browsing experience and to analyze our traffic. com uses cookies on this site. 12, 2019 (GLOBE NEWSWIRE) -- Theratechnologies Inc. TH1902 is currently Theratechnologies’ lead investigational PDC candidate for the treatment of cancer derived from its SORT1+ Technology™. (“Theratechnologies”) with the Securities and Exchange Commission (the. 2015 Peel Street, 11th Floor Montréal, Québec Canada H3A 1T8 Phone: 514 336-7800 Fax: 514 331-9691Theratechnologies Announces Amendment to its Term Loan Facility With Affiliates of Marathon Asset Management. 3089 Background: SORT1 is expressed in a variety of tumors when compared to most healthy tissue. 51 S1. (TH) has had its first patient receive a dose of TH1902, for the treatment of sortilin positive (SORT1+) solid tumours. GUD | Complete Knight Therapeutics Inc. TH1902, the leading product candidate derived from the SORT1+ Technology, is a first-in-class peptide-drug. com uses cookies on this site. is a pharmaceutical company, which engages in addressing medical needs of patients with Human Immunodeficiency Virus (HIV). Theratechnologies is leveraging its SORT1+ Technology™ to develop a new class of therapy that targets sortilin (SORT1)-positive cancers by linking anticancer drugs to proprietary peptides that specifically bind to the sortilin receptor. MONTREAL, Sept. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that President and CEO, Paul Lévesque has issued an open letter to. Theratechnologies affirms fiscal 2022 revenue to be in the range of $79 million and $84 million for full fiscal 2022, or growth of the commercial portfolio to be in the range of 13% and 20% as. Second quarter 2022 earnings: Revenues miss analyst expectations Jul 15. Biopharmaceutical company Theratechnologies Inc. Stockhouse. This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated December 16, 2021 to its. 7 ( 1D) About THTX In 2022, THTX's revenue was 80. 35 as of 10:41 a. 9%, while the Biotechs industry saw earnings growing at 17. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. We also use them to share usage. BioSyent then managesthese products through the regulatory process and product registration (approval); and once approved, BioSyent markets these products throughout Canada. Cookies are used to offer you a better browsing experience and to analyze our traffic. A high-level overview of Theratechnologies Inc. (NASDAQ:THTX) Q3 2021 Earnings Call October 13, 2021 8:30 A. Theratechnologies’ Ibalizumab Demonstrates Cost-Effectiveness as an Addition to Routine Clinical Care in Heavily Treatment-Experienced People with HIV. The Theratechnologies Inc. FAQ – Émetteurs inscrits NOUVEAU. $103. (TSX: TH) (NASDAQ: THTX) (“Theratechnologies”), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it will report financial results for its first quarter 2023 ended February 28, on Wednesday, April. Theratechnologies Inc. MONTREAL, June 29, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. 06 million, an increase of 14. TMX Group Limited and its affiliates do not endorse or recommend any securities issued by any companies identified on, or linked through, this site. US Headquarters. home message. com uses cookies on this site. Theratechnologies Inc. View real-time stock prices and stock quotes for a full financial overview. By continuing to use our service, you agree to our use of cookies. com uses cookies on this site. Cookies are used to offer you a better browsing experience and to analyze our traffic. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has decided to pause the enrollment of patients in its Phase 1 clinical trial of. ASP | Complete Acerus Pharmaceuticals Corp. com. MONTREAL, April 12, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. About Theratechnologies. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, is pleased to announce that new data featuring its investigational sortilin 1 (SORT1)-targeting peptide-drug conjugate technology will be presented in three posters at the American. - Cash, bonds and money market funds of US$22. MONTREAL, July 12, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. S. This is the list of the largest public listed companies in the Drug Manufacturers—Specialty & Generic industry from Canada by market capitalization with links to their reference stock. FAQ – Utilisateurs de TMX Argent NOUVEAU. Theratechnologies Announces 1-for-4 Reverse Stock Split. View real-time stock prices and stock quotes for a full financial overview. Theratechnologies Provides Details About R&D Day Webcast. Share your ideas and get valuable insights from the community of like minded traders and investors Headquarters. com uses cookies on this site. MONTREAL, March 31, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. 74M. NCU. Senior Director, Investor Relations. GlobeNewswire. 01, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Cookies are used to offer you a better browsing experience and to analyze our traffic. (TSX: TH, Forum) noted that its Q1 2022 consolidated sales grew 20%, supported by 35% growth in sales of EGRIFTA SV formulation. 00%. Headquartered in Montreal, Quebec (Canada), Theratechnologies commercializes two medicines in HIV and has research programs in HIV, NASH and Oncology. Gain a better understanding of ETFs with our ETF Insights and ETF 101 resource. View recently published Stock News reports from independent reports and journalists. . (2015-07-23 | TSX:TH) Theratechnologies Announces $9,600,000 Firm Offering of Units and Filing of Preliminary Short Form Prospectus. has received a $100 million binding commitment with respect to a non-dilutive term loan with an affiliate of Marathon Asset Management. Cookies are used to offer you a better browsing experience and to analyze our traffic. This work is well underway and will be considered by the SAC as part of their meeting, which is scheduled for the latter half of March when the analyses are expected to be ready. 04) earnings per share (EPS) for the quarter. Cookies are used to offer you a better browsing experience and to analyze our traffic. Theratechnologies Stock (NASDAQ: THTX) stock price, news, charts, stock research, profile. We also use them to share usage. 03, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Stockhouse. MONTREAL, Oct. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. 22, 2023 (GLOBE NEWSWIRE) -- B2Gold Corp. Cookies are used to offer you a better browsing experience and to analyze our traffic. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced receipt of a notification letter (the “Notification Letter. (TSX: TH) (NASDAQ: THTX) (“Theratechnologies”), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it will report financial results for its fourth quarter and full year fiscal 2022 ended November 30, on Tuesday, February 28, 2023. (882) posted 3 minutes ago. Theratechnologies is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies. This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated December 16, 2021 to its short form base shelf prospectus dated December 14, 2021. (TSX: TH) announced today that the Supreme Court of Canada has granted its appeal and dismissed 121851 Canada Inc. ("Theratechnologies" or the "Company"). TO) stock quote, history, news and other vital information to help you with your stock trading and investing. By continuing to use our service, you agree to our use of cookies. 00 in the next twelve months. S. (“Theratechnologies” or “the Company”) (TSX: TH) (NASDAQ: THTX), a. (THTX) Stock Price, Quote, latest community messages, chart, news and other stock related information. Theratechnologies had a negative net margin of 36. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX) today announced the publication of a preclinical study demonstrating the in vitro and in vivo efficacy of TH1902, an investigational sortilin (SORT1)-targeted peptide-drug conjugate, in inhibiting ovarian cancer and triple-negative breast cancer (TNBC. ET. Marsolais’ presentation will be available through. Data Link's cloud-based technology platform allows you to search, discover and access data and analytics for seamless integration via cloud APIs. We also use them to share usage. By continuing to use our service, you agree to our use of cookies. Theratechnologies (TSX:TH) has announced a loan of up to US$100M from Marathon Asset Management. Theratechnologies (Nasdaq: THTX) (TSX: TH) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Cookies are used to offer you a better browsing experience and to analyze our traffic. About TH1902. 4 million.